Irontophoresis™: Transdermal delivery of iron by iontophoresis

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2670-2676

  Murthy, S Narasimha ^a   Vaka, Siva Ram Kiran ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Anemia; Ferric pyrophosphate; Iontophoresis

Indexed keywords

FERRIC PYROPHOSPHATE; FERROVER; IRON; IRON DERIVATIVE; TRANSFERRIN; UNCLASSIFIED DRUG; PYROPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DIFFUSION; DRUG PENETRATION; IONTOPHORESIS; IRON BLOOD LEVEL; IRONTOPHORESIS; NONHUMAN; RAT; SKIN PERMEABILITY; ANIMAL; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HAIRLESS RAT; IN VITRO STUDY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; DIPHOSPHATES; DRUG DELIVERY SYSTEMS; IONTOPHORESIS; IRON; RATS; RATS, HAIRLESS; SKIN ABSORPTION;

EID: 68249097422     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21641     Document Type: Article

References (14)

1. Milman N, Byg K, Bergholt T, Eriksen L, Hvas A. 2006. Body iron and individual iron prophylaxis in pregnancy-Should the iron dose be adjusted according to serum ferritin? Ann Hematol 85: 567-573.
2. Hoen B, Kessler M, Gestin D, Mayeux D. 1995. Risk factors for bacterial infections in chronic hemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10:377-381.
3. Tapiero H, Gate L, Tew KD. 2001. Iron: Deficiencies and requirements. Biomed Pharmacother 55:324-332.
4. Schultink W, van der Ree M, Matulessi P, Gross R. 1993. Low compliance with the iron-supplementation program: A study among pregnant women in Jakarta, Indonesia. Am J Clin Nutr 57:135-139. (Pubitemid 23039882)
5. Schaefer RM, Schaefer L. 1998. Iron monitoring and supplementation: How do we achieve the best results? Nephrol Dial Transplant 13:9-12.
6. Hamstra RD, Block MH, Schocket AL. 1980. Intravenous iron dextran in clinical medicine. JAMA 243:1726-1731.
7. Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, Th de Jong GM. 1996. Oversaturation of transferrin after intravenous ferric gluconate (Ferrlecit B) in hemodialysis patients. Nephrol Dial Transplant 11:820-824. (Pubitemid 26148673)
8. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer Rm. 2001. A randomized, controlled parallel group trial on efficacy and safety of iron sucrose (Venofer1) vs iron gluconate (Ferrlecit1) in hemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 16:1239-1244. (Pubitemid 32547381)
9. Gupta A, Amin NB, Besarab A. 1999. Dialysate iron therapy: Inclusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 55:1891-1898. (Pubitemid 29197977)
10. Ringbom A. 1963. Complexation in analytical chemistry: A guide for the critical selection of analytical methods based on complexation reactions in chemical analysis. In: Elving PJ, Kolthoff IM, editors. 16 New York: Interscience Publishers.
11. Gupta A, Crumbliss AL. 2000. Treatment of iron deficiency anemia: Are monomeric iron compounds suitable for parenteral administration? J Lab Clin Med 136:371-378.
12. Morgan EH. 1977. Iron exchange between transferring molecules mediated by phosphate compounds and other cell metabolites. Biochim Biophys Acta 499:169-177.
13. Konopka K, Mareschal JC, Crichton RR. 1980. Iron transfer from transferrin to ferrin mediated by pyrophosphate. Biochim Biophys Res Commun 96:1408-1413. (Pubitemid 11223300)
14. Cavill I. 2003. Intravenous iron as adjuvant therapy: A two-edged sword? Nephrol Dial Transplant 18:24-28.